TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Reimbursement Of Some Anticancer Drugs Expected To Drop Sharply Under HHS Policy. June 30, 2000
TCL Archive Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.” July 18, 2008
TCL Archive US Preventive Services Task Force To Downgrade PSA Screening From “I” to “D” — As In “Don’t Do it.” October 6, 2011
